Use Of Mesenchymal Stem Cells For The Improvement Of Affective And Cognitive Function
AssigneeAriel-University Research and Development Company Ltd.
InventorsGadi Turgeman, Matanel Tfilin, Nikoli Gobshtise
Life of this patent
Estimating the term…
Abstract
Disclosed is the use of mesenchymal stem cells (MSCs) and in particular MSCs pretreated with pituitary adenylate cyclase-activating polypeptide (PACAP) or analogs and fragments of PACAP, for treatment of neurodegenerative and psychiatric diseases, and for the improvement of affective and cognitive function in a normal individual or in an individual suffering from a neurodegenerative or neuropsychiatric disease.
Claims20
A method of improving cognitive function of a subject, the method comprising pretreatment of mesenchymal stem cells (MSCs) with at least one agent selected from the group consisting of pituitary adenylate cyclase-activating polypeptide (PACAP) or analogs or fragments thereof, dehydroepiandrosterone (DHEA) and lithium chloride (LiCl);
- and administering to said subject a pharmaceutically effective amount of the MSCs thereby improving the cognitive function of said subject.
A method for generating mesenchymal stem cells (MSCs) comprising culturing MSCs in the presence of an effective amount of at least one agent selected from the group consisting of pituitary adenylate cyclase-activating polypeptide (PACAP) or analogs or fragments thereof, dehydroepiandrosterone (DHEA) and lithium chloride (LiCl).
A method of treating schizophrenia in a subject in need thereof, the method comprising administering to said subject a pharmaceutically effective amount of MSCs.
Dependencies are inferred from the claim text.